Influence of menopause and aging on clinical outcomes in schizophrenia
Aspect | Outcomes | Findings |
---|---|---|
Epidemiology | Reduced levels of oestrogens on schizophrenia incidence | Second peak of incidence at menopause in women [25, 73] |
Psychopathological symptoms | Symptom severity and clinical stability | Menopause correlates with 1) increased severity of psychosis [74] and 2) antipsychotic resistance [74–82] |
Physical health | Breast cancer—incidence and mortality | Increased incidence attributed to drug-induced hyperprolactinemia. Increased mortality attributed to low rates of cancer screening and medical neglect [83, 84] |
Medical co-morbidity | Osteoporosis and type 2 diabetes attributed to antipsychotics [82] |